CardioGenesis Corp.

Medicare panel's review of myocardial revascularization complete

Published in Biotech Law Weekly, August 20th, 2004

CardioGenesis Corp. (CGCP), a company focused on surgical products and accessories used in angina-relieving transmyocardial revascularization (TMR) and percutaneous myocardial revascularization procedures, announced the Medicare Coverage Advisory Committee (MCAC) reviewed more than 6 years of clinical evidence regarding laser myocardial revascularization as a treatment for patients suffering from severe angina pain.

The committee members' assessments of the clinical evidence will be forwarded to the Centers for Medicare & Medicaid Services (CMS), the government agency charged with making medical coverage decisions for Medicare. CMS does not have any pending national...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Law Weekly

Source: Biotech Law Weekly (2004-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry